Thiazolidinedione use and the risk of fractures

CMAJ. Canadian Medical Association Journal

Volumn 180, Issue 8, 2009, Pages 841-842

  Toulis, Konstantinos A ^a   Goulis, Dimitrios G ^a   Anastasilakis, Athanasios D ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

PIOGLITAZONE; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 2,4-THIAZOLIDINEDIONE; ANTIDIABETIC AGENT;

CONFIDENCE INTERVAL; FRACTURE; HUMAN; LETTER; MEDICAL RESEARCH; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK ASSESSMENT; SENSITIVITY ANALYSIS; BONE DENSITY; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FEMALE; FOLLOW UP; GREECE; INCIDENCE; MALE; REFERENCE VALUE; RISK;

BONE DENSITY; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; FRACTURES, BONE; GREECE; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; ODDS RATIO; REFERENCE VALUES; RISK ASSESSMENT; THIAZOLIDINEDIONES;

EID: 65349193855     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.1090003     Document Type: Letter

References (2)

1. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009;180:32-9.
2. Song F, Altman DG, Glenny AM, et al. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003;326:472.